Celltrion’s injectable infliximab has taken over 32% share in major European markets. What’s driving adoption?
Celltrion will highlight long-term and real-world evidence for Remsima SC at UEG Week 2026 in Barcelona, alongside its recently introduced liquid intravenous formulation and wider IBD biosimilar portfolio. The programme reinforces a commercialization strategy supported by randomized maintenance studies, although the conference announcement does not disclose new efficacy results.